[go: up one dir, main page]

GT201300018A - Compuestos heterociclicos agonistas del receptor ip - Google Patents

Compuestos heterociclicos agonistas del receptor ip

Info

Publication number
GT201300018A
GT201300018A GT201300018A GT201300018A GT201300018A GT 201300018 A GT201300018 A GT 201300018A GT 201300018 A GT201300018 A GT 201300018A GT 201300018 A GT201300018 A GT 201300018A GT 201300018 A GT201300018 A GT 201300018A
Authority
GT
Guatemala
Prior art keywords
receiver
agonist
derivatives
heterociclic compounds
heterociclic
Prior art date
Application number
GT201300018A
Other languages
English (en)
Inventor
Charlton Steven John
Leblanc Catherine
Mckeown Stephen Carl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201300018A publication Critical patent/GT201300018A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA DERIVADOS HETEROCÍCLICOS QUE ACTIVAN EL RECEPTOR DE IP. LA ACTIVACIÓN DE LA VÍA DE SEÑALIZACIÓN DEL RECEPTOR DE IP ES ÚTIL PARA TRATAR MUCHAS FORMAS DE HAP, FIBROSIS PULMONAR Y EJERCER EFECTOS BENEFICIOSOS EN CONDICIONES FIBRÓTICAS DE DIVERSOS ÓRGANOS EN MODELOS ANIMALES Y EN PACIENTES. LAS COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN TALES DERIVADOS TAMBIÉN ESTÁN ABARCADOS.
GT201300018A 2010-07-14 2013-01-14 Compuestos heterociclicos agonistas del receptor ip GT201300018A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36413510P 2010-07-14 2010-07-14

Publications (1)

Publication Number Publication Date
GT201300018A true GT201300018A (es) 2015-11-24

Family

ID=44628483

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201300018A GT201300018A (es) 2010-07-14 2013-01-14 Compuestos heterociclicos agonistas del receptor ip

Country Status (35)

Country Link
US (2) US8754085B2 (es)
EP (1) EP2593452B1 (es)
JP (1) JP5781159B2 (es)
KR (1) KR101491938B1 (es)
CN (1) CN103097385B (es)
AU (1) AU2011278279C1 (es)
BR (1) BR112013000946B1 (es)
CA (1) CA2804744C (es)
CL (1) CL2013000104A1 (es)
CO (1) CO6660445A2 (es)
CR (1) CR20130012A (es)
CU (1) CU24147B1 (es)
CY (1) CY1118819T1 (es)
DK (1) DK2593452T3 (es)
EA (1) EA022046B1 (es)
EC (1) ECSP13012385A (es)
ES (1) ES2622519T3 (es)
GT (1) GT201300018A (es)
HR (1) HRP20170617T1 (es)
HU (1) HUE031710T2 (es)
IL (1) IL224164A (es)
LT (1) LT2593452T (es)
MA (1) MA34373B1 (es)
MX (1) MX2013000537A (es)
MY (1) MY156795A (es)
NZ (1) NZ605528A (es)
PE (1) PE20130404A1 (es)
PH (1) PH12013500084A1 (es)
PL (1) PL2593452T3 (es)
PT (1) PT2593452T (es)
RS (1) RS55856B1 (es)
SG (1) SG186989A1 (es)
SI (1) SI2593452T1 (es)
UA (1) UA109786C2 (es)
WO (1) WO2012007539A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013500084A1 (en) 2010-07-14 2015-09-11 Novartis Ag Ip receptor agonist heterocyclic compounds
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
UY34572A (es) 2012-01-13 2013-09-02 Novartis Ag Compuestos heterocíclicos agonistas del receptor ip
WO2013105063A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2013105061A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused dihydropyrido [2,3 -b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US9115129B2 (en) 2012-01-13 2015-08-25 Novartis Ag Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
ES2561353T3 (es) 2012-01-13 2016-02-25 Novartis Ag Sales de un agonista del receptor IP
CN105189500A (zh) 2013-02-13 2015-12-23 诺华股份有限公司 Ip受体激动剂杂环化合物
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
BR112016023967A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de pirazina como inibidores de fosfatidilinositol 3-cinase
CN106458979B (zh) 2014-04-24 2020-03-27 诺华股份有限公司 作为磷脂酰肌醇3-激酶抑制剂的氨基吡嗪衍生物
EP3134396B1 (en) 2014-04-24 2019-09-18 Novartis AG Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
TWI806832B (zh) * 2016-07-12 2023-07-01 美商銳新醫藥公司 作為異位shp2抑制劑之2,5-雙取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪
AU2017378409A1 (en) 2016-12-14 2019-07-04 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
AR110401A1 (es) 2016-12-21 2019-03-27 Chiesi Farm Spa Derivados dihidropirimidina bicíclica-carboxamida como inhibidores de rho-quinasa
AU2018210770B2 (en) 2017-01-23 2022-03-24 Revolution Medicines, Inc. Bicyclic compounds as allosteric SHP2 inhibitors
BR112019014527A2 (pt) 2017-01-23 2020-02-27 Revolution Medicines, Inc. Compostos de piridina como inibidores de shp2 alostéricos
PE20191744A1 (es) 2017-01-30 2019-12-12 Chiesi Farm Spa Derivados de tirosinamida como inhibidores de rho-quinasa
JP2020527593A (ja) * 2017-07-18 2020-09-10 ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． １，８−ナフチリジノン化合物およびその使用
EP3654978A4 (en) 2017-07-18 2021-03-31 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS USED AS ADENOSINE ANTAGONISTS
MA50074A (fr) 2017-09-07 2021-04-28 Chiesi Farm Spa Dérivés d'analogues de tyrosine en tant qu'inhibiteurs de rho-kinase
BR112020007058A2 (pt) 2017-10-12 2020-10-06 Revolution Medicines, Inc. compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
WO2019118909A1 (en) 2017-12-15 2019-06-20 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
US11725007B2 (en) 2017-12-18 2023-08-15 Chiesi Farmaceutici S.P.A. Meta tyrosine derivatives as rho-kinase inhibitors
MA51284A (fr) 2017-12-18 2021-05-26 Chiesi Farm Spa Dérivés d'oxadiazole en tant qu'inhibiteurs de kinase rho
EP3728248B1 (en) 2017-12-18 2022-02-02 Chiesi Farmaceutici S.p.A. Azaindole derivatives as rho-kinase inhibitors
AR114926A1 (es) 2018-06-13 2020-10-28 Chiesi Farm Spa Derivados de azaindol como inhibidores de rho-quinasa
TW202019923A (zh) 2018-07-16 2020-06-01 義大利商吉斯藥品公司 作為Ｒｈｏ－激酶抑制劑之酪胺酸醯胺衍生物
US11254670B2 (en) 2019-01-18 2022-02-22 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
WO2020150675A1 (en) * 2019-01-18 2020-07-23 Nuvation Bio Inc. Compounds and uses thereof
MX2021008650A (es) 2019-01-18 2021-11-03 Nuvation Bio Inc Compuestos heterociclicos como antagonistas de adenosina.
EP4263547B1 (en) 2020-12-15 2025-07-02 Chiesi Farmaceutici S.p.A. Dihydrofuropyridine derivatives as rho- kinase inhibitors
EP4263546B1 (en) 2020-12-15 2025-07-02 Chiesi Farmaceutici S.p.A. Dihydrofuropyridine derivatives as rho- kinase inhibitors
CN116568304A (zh) 2020-12-15 2023-08-08 奇斯药制品公司 作为rho-激酶抑制剂的二氢呋喃并吡啶衍生物
WO2023110700A1 (en) 2021-12-13 2023-06-22 Chiesi Farmaceutici S.P.A. Dihydrofuropyridine derivatives as rho-kinase inhibitors

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1454864A (en) 1974-03-05 1976-11-03 Wyeth John & Brother Ltd Thioureas
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
CA2090283A1 (en) 1992-02-28 1993-08-29 Nobuyuki Hamanaka Phenoxyacetic acid derivatives
US5516652A (en) 1993-10-06 1996-05-14 Merck Frosst Canada Inc. DNA encoding prostaglandin receptor IP
WO1995021863A1 (en) 1994-02-10 1995-08-17 Ono Pharmaceutical Co., Ltd. Prostaglandin i2 receptor
WO1996035713A1 (en) 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
TWI242011B (en) 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
UA71586C2 (en) 1998-12-04 2004-12-15 Smithkline Beecham Corp A vitronectin receptor antagonist
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
SK286968B6 (sk) 1999-05-04 2009-08-06 Schering Corporation Piperidín-piperidinyl ako CCR5 antagonista, farmaceutický prostriedok s jeho obsahom a jeho použitie
WO2000066558A1 (en) 1999-05-04 2000-11-09 Schering Corporation Piperazine derivatives useful as ccr5 antagonists
GB9914255D0 (en) 1999-06-18 1999-08-18 Lilly Forschung Gmbh Pharmaceutical compounds
EG24179A (en) 1999-09-07 2008-09-28 Smithkline Beecham Corp Vitronectin receptor antagonists
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
BR0014076A (pt) 1999-09-17 2002-10-15 Millennium Pharm Inc Benzamidas e inibidores correlatos do fator xa
HUP0203246A3 (en) 1999-11-08 2003-12-29 Merck & Co Inc Process and intermediates for the preparation of imidazolidinone alpha v integrin antagonists
DE60016047T2 (de) 2000-01-03 2005-11-03 Pharmacia Corp., Chicago Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
JP2003522142A (ja) 2000-02-08 2003-07-22 スミスクライン・ビーチャム・コーポレイション 炎症性疾患の治療法および治療用組成物
NZ521028A (en) * 2000-03-16 2004-07-30 F Carboxylic acid derivatives as IP antagonists
AP2002002647A0 (en) 2000-04-10 2002-12-31 Pfizer Prod Inc Benzoamide piperidine compounds as substance p antagonists
US7119207B2 (en) 2000-04-10 2006-10-10 Pfizer Inc Benzoamide piperidine containing compounds and related compounds
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
TWI316055B (es) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
TW200305423A (en) 2002-02-14 2003-11-01 Ono Pharmaceutical Co N-carbamoyl nitrogen-containing condensed ring compound and medicament containing same as active ingredient
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
ES2201907B1 (es) 2002-05-29 2005-06-01 Almirall Prodesfarma, S.A. Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos.
SE0202483D0 (sv) 2002-08-21 2002-08-21 Astrazeneca Ab Chemical compounds
JP2006096662A (ja) 2002-09-18 2006-04-13 Sumitomo Pharmaceut Co Ltd 新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤
BR0314304A (pt) 2002-09-18 2005-07-26 Ono Pharmaceutical Co Drogas e derivados de triazapiro[5.5]undecano compreendendo o mesmo como o ingrediente ativo
JP2004107299A (ja) 2002-09-20 2004-04-08 Japan Energy Corp 新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
EP1631570A1 (en) 2003-03-12 2006-03-08 Abbott Laboratories Naphthyridine derivatives as antibacterial agents
MXPA05011523A (es) 2003-04-30 2006-01-23 Inst For Pharm Discovery Inc Heteroarilos sustituidos como inhibidores de proteinas de tirosina fosfatasas.
WO2005020926A2 (en) 2003-08-28 2005-03-10 Pharmacia Corporation Treatment or prevention of vascular disorders with cox-2 inhibitors in combination with cyclic amp-specific phosphodiesterase inhibitors
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
AU2004293133A1 (en) 2003-11-25 2005-06-09 High Point Pharmaceuticals, Llc Novel salicylic anilides
DE602004025504D1 (de) 2003-12-23 2010-03-25 Novartis Ag Bicyclische heterocyclische p-38-kinase-inhibitoren
GB0413960D0 (en) 2004-06-22 2004-07-28 Novartis Ag Organic compounds
AR051780A1 (es) 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
EP2392328A1 (en) 2005-05-09 2011-12-07 Hydra Biosciences, Inc. Compounds for modulating TRPV3 Function
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
AR056043A1 (es) 2005-08-25 2007-09-12 Schering Corp Agonistas de receptores adrenergicos alfa2c funcionalmente selectivos
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US7541371B2 (en) 2006-02-20 2009-06-02 Eisai R&D Management Co., Ltd. Method for treating a motor neuron disease
US20080064871A1 (en) 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds
US20080305169A1 (en) 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
US8163817B2 (en) 2007-05-11 2012-04-24 Canon Kabushiki Kaisha Aqueous ink, ink set, image forming method and image forming apparatus
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US20090054304A1 (en) * 2007-08-23 2009-02-26 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
US8501959B2 (en) 2008-06-24 2013-08-06 Panmira Pharmaceuticals, Llc Cycloalkane[B]indole antagonists of prostaglandin D2 receptors
JP2011528369A (ja) 2008-07-16 2011-11-17 シェーリング コーポレイション 二環式ヘテロ環誘導体およびそれらの使用方法
DE102008039082A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
TWI368513B (en) 2009-04-30 2012-07-21 Univ Kaohsiung Medical Synthesis of pulmodil and pulmodil-1, two chlorophenylpiperazine salt derivatives, and rhokinase-dependent inhibition activity on pulmonary artery endothelium dysfunction, medial wall thickness and vascular obstruction thereof
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
PH12013500084A1 (en) 2010-07-14 2015-09-11 Novartis Ag Ip receptor agonist heterocyclic compounds
UY34572A (es) 2012-01-13 2013-09-02 Novartis Ag Compuestos heterocíclicos agonistas del receptor ip
ES2561353T3 (es) 2012-01-13 2016-02-25 Novartis Ag Sales de un agonista del receptor IP
US9115129B2 (en) 2012-01-13 2015-08-25 Novartis Ag Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
EP2802581A1 (en) 2012-01-13 2014-11-19 Novartis AG 7,8- dihydropyrido [3, 4 - b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2013105061A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused dihydropyrido [2,3 -b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2013105063A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders

Also Published As

Publication number Publication date
IL224164A (en) 2016-08-31
CN103097385A (zh) 2013-05-08
AU2011278279B2 (en) 2014-08-07
KR101491938B1 (ko) 2015-02-10
MY156795A (en) 2016-03-31
DK2593452T3 (en) 2017-04-24
ECSP13012385A (es) 2013-03-28
CN103097385B (zh) 2016-08-03
US9132127B2 (en) 2015-09-15
US20140243346A1 (en) 2014-08-28
PE20130404A1 (es) 2013-04-17
HUE031710T2 (en) 2017-07-28
CO6660445A2 (es) 2013-04-30
LT2593452T (lt) 2017-04-10
CA2804744C (en) 2019-05-28
EP2593452A1 (en) 2013-05-22
NZ605528A (en) 2015-02-27
CY1118819T1 (el) 2018-01-10
SG186989A1 (en) 2013-02-28
MA34373B1 (fr) 2013-07-03
EA201300118A1 (ru) 2013-06-28
WO2012007539A9 (en) 2012-11-01
MX2013000537A (es) 2013-01-29
CA2804744A1 (en) 2012-01-19
AU2011278279A1 (en) 2013-02-21
US8754085B2 (en) 2014-06-17
PT2593452T (pt) 2017-04-24
UA109786C2 (xx) 2015-10-12
SI2593452T1 (sl) 2017-06-30
BR112013000946A2 (pt) 2016-05-17
RS55856B1 (sr) 2017-08-31
CU20130009A7 (es) 2013-04-19
JP2013531025A (ja) 2013-08-01
PH12013500084A1 (en) 2015-09-11
AU2011278279C1 (en) 2014-11-27
JP5781159B2 (ja) 2015-09-16
PL2593452T3 (pl) 2017-07-31
BR112013000946B1 (pt) 2020-09-08
HRP20170617T1 (hr) 2017-06-30
CR20130012A (es) 2013-02-19
CL2013000104A1 (es) 2013-05-17
KR20130038924A (ko) 2013-04-18
US20130102611A1 (en) 2013-04-25
CU24147B1 (es) 2016-02-29
EA022046B1 (ru) 2015-10-30
WO2012007539A1 (en) 2012-01-19
EP2593452B1 (en) 2017-01-18
ES2622519T3 (es) 2017-07-06

Similar Documents

Publication Publication Date Title
GT201300018A (es) Compuestos heterociclicos agonistas del receptor ip
MX381313B (es) Derivados de benzimidazol como moduladores de ror-gamma
MX385332B (es) Moduladores de ror-gamma.
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
LT3925607T (lt) Farmacinė kompozicija, skirta gydyti ligas, kurias nulemia cistinės fibrozės transmembraninio laidumo reguliatorius
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
LT2726511T (lt) Kompozicijos, panaudojimai ir būdai, skirti metabolinių sutrikimų ir ligų gydymui
CR20130214A (es) Antagonistas del receptor del cgpr de piperidinona carboxamida azaindano
EA201492011A1 (ru) Безводные фармацевтические составы для местного применения
EA201500628A1 (ru) Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
UY33670A (es) Anticuerpos de oncostatina m humana y metodos de uso
CY1117745T1 (el) Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης
MX376122B (es) Composiciones de plinabulina.
LT2013015A (lt) Farmacinės kompozicijos
CL2016002839A1 (es) Derivados de carboxamida
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
CR20120570A (es) Heterociclilbencilpirazoles sustituidos y uso de los mismos
MX370430B (es) Antagonistas muscarínicos y sus combinaciones para el tratamiento de enfermedades de las vías respiratorias en caballos.
PL3544420T3 (pl) Zastosowanie kompozycji do konserwowania narządów/tkanek
MX379454B (es) Derivados de fluoroindol como moduladores alostéricos positivos del receptor m1 muscarínico.
TR201908151T4 (tr) İzoindolin türevleri.
BR112012021988A2 (pt) "pasteurizador com saída pulverizador controlada"
MX2015005734A (es) Metodos de tratamiento de enfermedades hepaticas.